Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.
about
Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolitesRisk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral TreatmentBiological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaquesLong-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.Simultaneous quantification of a non-nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positTenofovir-associated bone density loss.Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovirA pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylateA chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans.The New Epidemiology of HIV-Related Kidney Disease.Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B.Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.Acyclic nucleoside phosphonates: a key class of antiviral drugs.Tenofovir disoproxil fumarate for the treatment of HIV infection.A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committeeSteady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.Management of dyslipidemia in HIV-infected patients.Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir.Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana.Therapy of HIV infection.Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label studyManagement of HIV-infected patients with multidrug-resistant virus.Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection.Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy.New antiretroviral drugs in clinical use.The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.Review of tenofovir-emtricitabine.Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.Atriplatrade mark - HIV therapy in one pill.Serum Phosphate Predicts Early Mortality among Underweight Adults Starting ART in Zambia: A Novel Context for Refeeding Syndrome?Association of tenofovir exposure with kidney disease risk in HIV infection.
P2860
Q28289901-C0E9A46A-42BA-4730-A008-B513A8FF9571Q28554081-2B949AEA-205C-4D43-9AFC-BBCFAEAC88FDQ28775900-63FBF935-162D-4BB0-B3CD-BDA98C79671BQ30983924-604585F2-C933-4335-ADA1-432BF5C01937Q33378148-7DCE2848-B658-4E27-925C-85451FF83E92Q33635034-7DEAE4B5-9928-4B26-90C0-28F6869FCF3BQ33769993-590669CA-92D1-4DED-B502-41C5C96D2E31Q33985702-5CBE536D-A50F-4AAE-B385-9E6247B6D861Q34032537-B7F0D592-CD1C-4EC0-9232-C82061FE160CQ34077060-D30A9E85-8656-43DE-A7D9-FA6EDEEE9A40Q34301401-9CD8B587-B6EB-4E0F-B396-62EF612D475CQ34307868-1C14F926-1362-4894-A7BB-C89678F31B47Q34382099-79BA2641-C1B7-485F-8BFA-8011D55FD670Q34409132-DB6C68B6-40E7-4AA0-89E2-111E6D05F3D5Q34464655-CA7F5F6B-3893-4FA8-B014-267B4FDA0EB3Q34569309-8B2FAF56-496B-4AC0-A73F-34C6495D225CQ35024683-72A59486-EBB1-40D7-B8C6-A21C11132874Q35124959-15E174C1-DAA8-4EE0-BED5-EC110BCFDA01Q35191539-88544B84-4763-432C-A21A-3A1D1E7760E5Q35643573-A5C3EFE3-7693-49E5-A296-B4CCF28C4DB0Q35852636-8541280B-E0C2-49C3-B3C8-06DC12396580Q35858002-2CE36AE0-5233-4F39-9E1E-5AD21E1AF8C3Q35967419-8C603AC5-27C2-4163-BBDE-B4288DE8ACACQ36097686-D2343DBA-F153-41B2-BBF3-0FDB2411AED3Q36105831-1202F253-491F-488B-A798-CA91AD07392CQ36223772-81AF57C6-AC12-451F-AB17-6612C49205C8Q36284159-C9758870-48BA-4548-B07F-510FAE9AD7B0Q36388067-111345FD-A6BD-45FD-89D8-E66564E384F1Q36407276-B388A380-7BEF-4BB6-8BA5-05601838BE21Q36425083-8B9E9333-39B6-4CEC-81B5-1232DF9F5A3FQ36429743-F2A59AA5-F83F-47F6-BCCE-312A6456B051Q36451062-41B4B48C-9F33-490B-885D-3A9F4A901924Q36525658-A539E5EA-10F9-4C55-9E3E-70DE09974BA8Q36558253-D4FF55E2-B764-40B3-830F-2AF959053DB5Q36607380-992E8EB4-94EB-437E-AFE6-ABAC0F951E72Q36663686-8472233E-D1AF-4CCF-9F1F-B862D3BD677BQ36723349-93A68E7A-32AE-48F3-9B81-9EC961F9C98CQ36818184-700EF558-CAF8-443C-9A1C-DC9D44FFF8D3Q36838130-C687D637-12CC-42BD-A22D-EEFE789571EDQ37077982-45A6E213-E301-428A-B136-011C4E50D306
P2860
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Tenofovir disoproxil fumarate ...... infection: a randomized trial.
@en
Tenofovir disoproxil fumarate ...... infection: a randomized trial.
@nl
type
label
Tenofovir disoproxil fumarate ...... infection: a randomized trial.
@en
Tenofovir disoproxil fumarate ...... infection: a randomized trial.
@nl
prefLabel
Tenofovir disoproxil fumarate ...... infection: a randomized trial.
@en
Tenofovir disoproxil fumarate ...... infection: a randomized trial.
@nl
P2093
P1476
Tenofovir disoproxil fumarate ...... infection: a randomized trial.
@en
P2093
Andrew Cheng
Anton L Pozniak
Corklin R Steinhart
Daniel Berger
Dion F Coakley
Gerald Pierone
John J Toole
Kathleen Squires
Michael D Miller
Michael Wulfsohn
P304
P356
10.7326/0003-4819-139-5_PART_1-200309020-00006
P407
P433
P577
2003-09-01T00:00:00Z